PROVIDER COVID-19 IMMUNIZATION CONSENT FORM

For COVID-19 Provider use only Clinic Name/Code: Location type: (clinic, health department, pharmacy, etc.,)				
Address:City:County:				
State: Zip Code: Date of Service: Person Receiving Vaccine: Date of Service:				
(Logal) First Name: MI: Last Name:				
(Legal) First Name: MI: Last Name: Date of Birth: / Age:				
1. MEDICAL HISTORY: Complete the following questions for the individual receiving the vaccine. If you answer "YES" you may not be able to receive the COVID-19 vaccine.				
If YES refer to following websites at <u>www.PfizerMedInfo.com</u> . Moderna <u>www.modernatx.com</u> . Janssen <u>www.janssencovid19vaccine.com</u>				
Refer to Pre-vaccination Checklist for COVID-19 vaccines to clarify questions:		YESN	O	
<u>vaccination-screening-form.pdf.</u>				
Have you had a previous COVID-19 vaccine? If yes, what type and date				
Do you have a fever today? Are you sick today? Do you have COVID-1	19 infection and are currently in isolation? Are you			
currently in quarantine for known exposure to COVID-19?				
Have you ever had an allergic reaction to a COVID-19 vaccine or a COVID-19 vaccine component (including polyethylene				
glycol [PEG], which is found in some medications, or laxatives, and preparations for colonoscopy; or polysorbate, which is				
found in some vaccines, coated tablets, or IV steroids)?				
Have you ever had an allergic reaction that caused hives, swelling, respirato				
vaccine other than COVID-19 vaccine or an injectable medication that required treatment with epinephrine (EpiPen) or treatment				
at a hospital? Severe reaction or anaphylaxis to food, pet, venom, environmental, or oral medication allergies are not contraindications or precautions to vaccination with any COVID-19 vaccine.				
Do you have a bleeding disorder or are you taking a blood thinner?				
Have you received a hematopoietic cell transplant (HCT) or CAR-T-cell therapy since receiving COVID-19 vaccine? You should				
be revaccinated with a primary vaccine series at least 12 weeks after transplant or CAR-T-cell therapy.				
Did you develop myocarditis or pericarditis after any dose of COVID-19 vaccine? You should not receive a subsequent dose of				
any COVID-19 vaccine. If you have developed myocarditis or pericarditis unrelated to an mRNA COVID vaccination, you_may				
receive COVID-19 vaccine after the episode has completely resolved.				
Are you immunocompromised? Do you have a condition that weakens your	immune system? Are you receiving any			
immunosuppressive therapy? You are eligible to receive any FDA-authorized or FDA-approved COVID-19 vaccine unless you				
have a contraindication for some other reason. However, you will need special counseling about the vaccine.				
Have you had history of Heparin-Induced Thrombocytopenia (HIT) or Thrombosis with Thrombocytopenia Syndrome (TTS)? You				
may receive Pfizer-BioNTech or Moderna COVID-19 vaccine.				
Have you had history of Thrombosis with Thrombocytopenia Syndrome (TTS) following Janssen or any other adenovirus-vector				
(AstraZeneca) COVID-19 vaccine? Those who developed TTS after the initial Janssen vaccine should not receive a Janssen or any				
other adenovirus-vector COVID-19 vaccine booster dose. You may receive a mRNA COVID-19 vaccine.				
Have you received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment or for post-exposure prophylaxis				
(PEP)? You may receive a COVID-19 vaccine. No delay to receive a COVID-19 vaccine is necessary.				
Have you had Multisystem Inflammatory Syndrome (MIS)? Defer vaccination	•			
COVID-19 vaccination should be between the patient, their guardian, clinica				
Have you had history of Guillain-Barre Syndrome (GBS)? People with a his				
approved COVID-19 vaccine. People who had GBS after receiving Janssen	vaccine should receive a Prizer-BioiN rech or Moderna			
COVID-19 vaccine booster at least 8 weeks after the Janssen dose. NOTE: CDC has made a clinical preference for persons 18 years and older to receive an mRNA COVID-19 vaccine over Janssen COVID-19				
vaccine. Patients who cannot or are unwilling to receive an mRNA vaccine will be able to access Janssen COVID-19 vaccine. The Janssen				
Fact Sheet must be provided and explained to the recipient or parent/legal representative about the risks and benefits and address any questions				
or concerns that the recipient or parent/legal representative may have prior to the vaccination. Recipients of Janssen COVID-19 vaccine should				
seek immediate medical attention if they develop shortness of breath, chest pain, leg pain or swelling, persistent abdominal pain, severe or				
persistent headaches or blurred vision, easy bleeding beyond the vaccination site within 30 days of a Janssen vaccination.				
NOTE: A second dose of COVID-19 vaccine may be due in 21 days or 28 days after initial vaccine. Refer to your COVID-19 vaccination				
record card for proof of initial vaccine date and for second dose due date. Contact your vaccination provider, PCP, or your ADH Local Health				
Unit in 21 days or 28 days for more information.				
2. RELEASE AND ASSIGNMENT: Please read the section				
on the reverse side of this form. The Providers Privacy Notice	My signature below indicates I have read, understand		1	
is available at the clinic site or accompanies this form.	agree to section 2. Release and Assignment of the C		-	
Then sign in the box at right.19 Immunization Consent Form and Vaccine Recipient			ļ	
Emergency Use of Authorization Fact Sheet (EUA).				

Please sign here

-

Date

Signature of Patient/Parent/Guardian:

i

RELEASE AND ASSIGNMENT:				
 I have read or had explained to me the Vaccine Recipient Emergency Use Authorization (EUA) Fact Sheet for COVID-19 vaccine risks and benefits. To read the Vaccine Recipient EUA Fact Sheet for Pfizer COVID-19 vaccine, Moderna COVID-19 vaccine, or Janssen COVID-19 vaccine visit <u>https://www.cdc.gov/vaccines/covid-19/eua/index.html</u> or visit your Local Health Unit or PCP to receive a printed copy of the EUA Fact Sheet. 				
• I give consent to this COVID-19 provider/staff for the individual named below to be vaccinated with COVID-19 vacc				
• I hereby acknowledge that I have reviewed a copy of the Provider's Privacy Notice.	- formation Sectors			
• I understand that information about this COVID-19 vaccination will be included in (WebIZ) Arkansas Immunization Information System. To My Insurance Carrier (s):				
• I authorize the release of any medical information necessary to process my insurance claim(s).				
 I authorize and request payment of medical benefits directly to this COVID-19 Provider. I agree that the authorization will cover all medical services rendered until I revoke the authorization. 				
 I agree that the authorization will cover all medical services rendered until revoke the authorization. I agree that the photocopy of this form may be used instead of the original. 				
	i			
PATIENT INFORMATION:				
(Legal) First Name: MI: Last Name:				
Date of Birth: / / / Gender: Male Female Phone #:				
Street Address: P.O. Box Apt. No				
City:State:Zip Code:				
Race: 🗌 Asian 🗌 Black/African American 🗋 Native American /Alaska Native 🗌 Native Hawaiian/Other Pacific Islander 🗌 White 🗋 Other				
Ethnicity: Hispanic/Latino Non-Hispanic				
INSURANCE STATUS (Check appropriate box):				
Patient's Relationship to Insurance Policy Holder: 🗌 Self 📄 Spouse 📄 Child 📄 Other				
Medicaid/ARKids Number:				
Medicare Number:				
Insurance Company Name:				
Member ID/Policy #:				
REQUIRED POLICY HOLDER INFORMATION:				
(Legal) First Name: MI: Last Name:				
Policy Holder Date of Birth: ///// Email Address:				
Policy Holder's Employer Name:				
COVID-19 VACCINE ADMINISTRATION (Completed by staff only)				
Co-administration of COVID-19 vaccines and other vaccines including flu vaccine. COVID-19 vaccines and other vaccines may be				
administered without regard to timing. This includes simultaneous administration of COVID-19 vaccin				
same visit. Other vaccines can also be administered any time before or after COVID-19 vaccination. Refer				
for COVID-19 vaccines to clarify medical history questions:www.cdc.gov/vaccines/covid-19/downloads/p form.pdf. Refer to Summary Document of Interim Clinical Considerations Summary Document for Interim				
of COVID-19 Vaccines Currently Authorized or Approved in the United States – Fact Sheet (cdc.gov).				
Ultra-cold COVID-19 Vaccine Frozen COVID-19 Vaccine Refrigerated CO	VID-19 Vaccine			
Pfizer (Gray Cap)Moderna (Light Blue label)AstraZeneca	Novavax-Matrix-M1			
	son & Johnson)			
Pfizer (Maroon Cap)Moderna (Magenta LabelOther COVID-Pfizer (Gray Cap Bivalent Booster)Moderna(Gray label Bivalent Booster)Other COVID-	-19 Vaccine			
Route Site Dosage mL MFG Lot Number Primary Dose	Bivalent			
Koute Site Dosage infl WFG Lot Number Frinary Dose Code Code Code Number	Booster Dose			

MFG Codes: PFR=Pfizer, MOD=Moderna, ASZ=AstraZeneca, JSN=Janssen, NVX=Novavax, MSD=Merck Site Codes: Right Deltoid = RD, Left Deltoid = LD, Right Leg = RL, Left Leg = LL, Right Arm = RA, Left Arm = LA

Signature and Title of Vaccine Administrator: ______ Date Vaccine Administered: _____ / ____ / _____ Initial Here: Uvaccine Administrator acknowledgment of providing the most current Janssen COVID-19 Fact Sheet to vaccine recipient (explaining the risk and benefits) and addressing any questions or concerns with the vaccine recipient prior to vaccination with Janssen

One Two

Three

Booster Dose

COVID-19.Revised 09/07/2022